2024
Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer
Rosenberg S, Zheng Y, Santos K, Riley E, Meadows H, Snow C, Hughes M, Frank E, Lin N, Partridge A, Winer E, Parsons H. Patient-reported outcomes, and perceptions and knowledge about recurrence in women with hormone receptor-positive breast cancer. Breast Cancer Research And Treatment 2024, 1-8. PMID: 39432162, DOI: 10.1007/s10549-024-07510-8.Peer-Reviewed Original ResearchBreast cancer survivorsEmotional healthBreast cancer risk perceptionBreast cancerCancer risk perceptionCollege degreeInaccurate risk perceptionsHR+ breast cancerLower educational attainmentPatient-reported outcomesRecurrence riskBreast cancer recurrenceRisk perceptionAssociated with overestimationCancer survivorsImprove risk communicationPROMIS AnxietyPopulation normsHormone receptor-positive breast cancerSurveyed patientsReceptor-positive breast cancerGeneral populationRisk overestimationYears post-treatmentLogistic regressionSecond primary non-breast cancers in young breast cancer survivors
Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Winer E, Bellon J, Partridge A. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Research And Treatment 2024, 207: 587-597. PMID: 38858235, DOI: 10.1007/s10549-024-07400-z.Peer-Reviewed Original ResearchPrimary non-breast cancerNon-breast cancerSubdistribution hazard ratiosYoung breast cancer survivorsStage 0-III BCBreast cancer survivorsConfidence intervalsGray subdistribution hazard modelRisk factorsMedical record reviewPrimary BCBreast cancerCumulative incidenceBC survivorsCancer survivorsYoung breast cancerSubdistribution hazard modelPrimary tumor characteristicsMedian follow-upRecord reviewType of malignancyGermline geneticsHazard ratioLong-term surveillancePatient factorsSecond Primary Breast Cancer in Young Breast Cancer Survivors
Brantley K, Rosenberg S, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Zheng Y, Kirkner G, Snow C, Winer E, Partridge A. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncology 2024, 10: 718-725. PMID: 38602683, PMCID: PMC11009864, DOI: 10.1001/jamaoncol.2024.0286.Peer-Reviewed Original ResearchGenetic testingYoung Women's Breast Cancer StudyYoung breast cancer survivorsBreast cancerBreast cancer survivorsYoung BC survivorsPrimary breast cancerGermline genetic testingIII BCMedical record reviewBreast Cancer StudyGermline pathogenic variantsPathogenic variantsBC survivorsTreatment decision-makingCancer survivorsFine-Gray subdistribution hazard modelCumulative incidencePV carriersSubdistribution hazard modelStage 0Patient surveyCharacterize risk factorsUnilateral mastectomyPrimary BC
2023
Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
Sella T, Zheng Y, Rosenberg S, Ruddy K, Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. Npj Breast Cancer 2023, 9: 31. PMID: 37185922, PMCID: PMC10130172, DOI: 10.1038/s41523-023-00529-y.Peer-Reviewed Original ResearchBreast cancer survivorsYoung Women's Breast Cancer StudyYoung breast cancer survivorsAdjuvant endocrine therapyCancer survivorsBreast Cancer StudyEndocrine therapyBreast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAromatase inhibitor monotherapyMulticenter prospective cohortPotential sociodemographic disparitiesRecurrence/deathRisk-based careReceipt of chemotherapyNon-Hispanic whitesWarrants further investigationPostmenopausal womenInhibitor monotherapyProspective cohortMultivariable analysisEligible participantsMean ageLongitudinal cohortDiet and physical activity interventions in Black and Latina women with breast cancer: A scoping review
Pichardo M, Sanft T, Ferrucci L, Romero-Ramos Y, Cartmel B, Harrigan M, Velazquez A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review. Frontiers In Oncology 2023, 13: 1079293. PMID: 36994212, PMCID: PMC10040823, DOI: 10.3389/fonc.2023.1079293.Peer-Reviewed Original ResearchBreast cancer survivorsPhysical activity interventionsLifestyle interventionCancer survivorsActivity interventionsLatina womenEfficacy trialsBreast cancerLatina breast cancer survivorsTrial of dietOne-year followFavorable behavioral changesBreast cancer diagnosisPrimary outcomeAvailable peer-reviewed literatureFuture trialsInformal care giversPilot trialSustained behavior changeEfficacy studiesHealthful lifestyleCare giversTrialsWeight lossCancer diagnosis
2022
A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
Chen W, Ballman K, Winer E, Openshaw T, Hahn O, Briccetti F, Irvin W, Pohlmann P, Carey L, Partridge A, Weiss A, McCall L, Matyka C, Carvan M, Holmes M. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial. Journal Of Clinical Oncology 2022, 40: 360922-360922. DOI: 10.1200/jco.2022.40.36_suppl.360922.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2-negative breast cancerStratified hazard ratioDisease-free survivalHazard ratioBreast cancerIDFS eventsAspirin usersCardiovascular diseaseGrade 3/4 adverse eventsAspirin/non-steroidal anti-inflammatory drugsNon-steroidal anti-inflammatory drugsAdjuvant aspirin therapyRandomized phase IIIRegular aspirin usersPlacebo-controlled trialDouble-blinded fashionBreast cancer survivorsBody mass indexBreast cancer trialsBreast cancer survivalBreast cancer recurrenceMultiple epidemiologic studiesAnti-inflammatory drugsAnti-tumor effects
2021
Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer
Freedman RA, Minami CA, Winer EP, Morrow M, Smith AK, Walter LC, Sedrak MS, Gagnon H, Perilla-Glen A, Wildiers H, Wildes TM, Lichtman SM, Loh KP, Brain EGC, Ganschow PS, Hunt KK, Mayer DK, Ruddy KJ, Jagsi R, Lin NU, Canin B, LeStage BK, Revette AC, Schonberg MA, Keating NL. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology 2021, 7: 609-615. PMID: 33507222, PMCID: PMC8944384, DOI: 10.1001/jamaoncol.2020.7582.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsBreast cancer eventsContralateral breast cancer eventsOlder breast cancer survivorsSurveillance mammographyClinician focus groupsCancer survivorsConsensus guidelinesCancer eventsLife expectancyEarly-stage breast cancerRoutine surveillance mammographyHigh-risk cancerClinical breast examinationExpert panelMultidisciplinary expert panelExpert consensus guidelinesIndividualized discussionGeriatric oncologyOlder patientsRoutine mammographyClinical findingsBreast examinationPatient preferencesPatient risk
2020
ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.
Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Openshaw T, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2020, 38: tps600-tps600. DOI: 10.1200/jco.2020.38.15_suppl.tps600.Peer-Reviewed Original ResearchInvasive disease-free survivalAspirin usersCardiovascular diseaseBreast cancerHER2-negative breast cancer patientsBlinded placebo-controlled trialHER2-negative breast cancerNegative breast cancer patientsRandomized phase IIIRegular aspirin usersPlacebo-controlled trialDisease-free survivalHormone receptor statusDouble-blinded fashionMonths of diagnosisBreast cancer survivorsTime of presentationBody mass indexBreast cancer patientsTherapy-Breast CancerBreast cancer survivalMultiple epidemiologic studiesNegative breast cancerAnti-tumor effectsDaily aspirin
2019
Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors
Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino A, Cartmel B, Harrigan M, Tolaney SM, Winer E, Ng K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors. JNCI Cancer Spectrum 2019, 4: pkz096. PMID: 32090192, PMCID: PMC7025659, DOI: 10.1093/jncics/pkz096.Peer-Reviewed Original ResearchBreast cancer survivorsPhase II trialCancer survivorsControl armII trialInsulin levelsRandomized phase II trialInsulin-like growth factor-1Insulin-like growth factorHomeostatic model assessmentCombination of exerciseSignificant weight lossGrowth factor-1Combination armMetformin useSecondary outcomesStandard therapyPrimary outcomeIntervention armInsulin resistanceDisease outcomeModality interventionsAnthropometric measurementsMetabolic markersMetabolic biomarkersABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.
Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2019, 37: tps599-tps599. DOI: 10.1200/jco.2019.37.15_suppl.tps599.Peer-Reviewed Original ResearchInvasive disease-free survivalAspirin usersCardiovascular diseaseBreast cancerHER2-negative breast cancer patientsHER2-negative breast cancerNegative breast cancer patientsRandomized phase IIIRegular aspirin usersTrial of aspirinDisease-free survivalHormone receptor statusDouble-blinded fashionMonths of diagnosisBreast cancer survivorsTime of presentationBody mass indexBreast cancer patientsTherapy-Breast CancerBreast cancer survivalMultiple epidemiologic studiesNegative breast cancerAnti-tumor effectsDaily aspirinIDFS events
2017
Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review
Freedman RA, Keating NL, Partridge AH, Muss HB, Hurria A, Winer EP. Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review. JAMA Oncology 2017, 3: 402-409. PMID: 27892991, PMCID: PMC5540165, DOI: 10.1001/jamaoncol.2016.3931.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsSurveillance mammographyAnticipated life expectancyOlder patientsBreast eventsBreast cancerCancer survivorsOlder survivorsHormonal therapyLife expectancyContralateral breast cancer riskOlder breast cancer survivorsAnnual surveillance mammographyIndividual riskPatient's individual riskCancer-related causesResidual breast tissueWomen 70 yearsBreast cancer riskBreast cancer screeningContralateral cancerMammographic surveillanceLocal therapyHealthy womenCancer screening
2014
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901
Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. Journal Of Cancer Survivorship 2014, 8: 627-637. PMID: 24917307, PMCID: PMC4386650, DOI: 10.1007/s11764-014-0371-5.Peer-Reviewed Original ResearchConceptsOlder breast cancer survivorsSurvivorship care plansBreast cancer survivorsCare plansCancer survivorsSCP receiptSurvivorship careOlder survivorsBreast cancer followCooperative group sitesNonmetastatic breast cancerPatient-reported outcomesCancer followSymptom burdenComorbid conditionsRecurrence surveillanceCancer patientsCancer sequelaePrimary careMethodsThree hundredBreast cancerCancer worryLower oddsOlder womenTelephone interviews
2013
Quality of life and symptoms in male breast cancer survivors
Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors. The Breast 2013, 22: 197-199. PMID: 23313328, DOI: 10.1016/j.breast.2012.12.014.Peer-Reviewed Original ResearchConceptsMale breast cancer survivorsBreast cancer survivorsQuality of lifeCancer survivorsProstate Cancer Index CompositeCancer Therapy-BreastFACT-B scoresHormonal scoresHormonal symptomsSymptom burdenBreast cancerStage 0Depression ScaleFunctional assessmentHospitalized AnxietyMale survivorsSymptomsSurvivorsSexual scaleOverall qualityScoresPatientsCancer
2012
Biomarkers of amenorrhea and ovarian function in breast cancer survivors.
Ruddy K, Gelber S, Tamimi R, Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. DOI: 10.1200/jco.2012.30.15_suppl.9071.Peer-Reviewed Original ResearchAnti-Mullerian hormoneBreast cancer survivorsOvarian functionBreast cancerCancer survivorsProspective multi-center cohort studyFollicle-stimulating hormone levelsMulti-center cohort studyYoung breast cancer survivorsResidual ovarian functionEarly breast cancerLast menstrual periodWilcoxon rank sum testRank sum testOvarian ablationEndocrine therapyOvarian suppressionCohort studyEligible womenFSH levelsOvarian reserveMedian ageOvarian dysfunctionSurvivorship periodMenopausal symptoms
2011
P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men.
Ruddy K, Giobbie-Hurder A, Giordano S, Goldfarb S, Kereakoglow S, Winer E, Partridge A. P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men. Cancer Research 2011, 71: p4-19-03-p4-19-03. DOI: 10.1158/0008-5472.sabcs11-p4-19-03.Peer-Reviewed Original ResearchExpanded Prostate Cancer Index CompositeBreast cancerMale breast cancer survivorsSexual functioningProstate Cancer Index CompositeSupportive care needsCancer Therapy-BreastHealth-related qualityMale breast cancerBreast cancer survivorsHormonal symptomsFertility counselingCancer survivorsSexual symptomsHealth perceptionSubstantial symptomsDepression ScaleCare needsFunctional assessmentSymptomsLarger studyCancer ResHospitalized AnxietyPsychological sequelaeCancerBreast Cancer Survivors' Perceptions of Survivorship Care Options
Mayer EL, Gropper AB, Neville BA, Partridge AH, Cameron DB, Winer EP, Earle CC. Breast Cancer Survivors' Perceptions of Survivorship Care Options. Journal Of Clinical Oncology 2011, 30: 158-163. PMID: 22162585, PMCID: PMC4874208, DOI: 10.1200/jco.2011.36.9264.Peer-Reviewed Original ResearchConceptsPrimary care physiciansBreast cancer survivorsNurse practitionersCancer survivorsVirtual visitsClinician typeSurvivor careCancer survivalBreast cancer survivors increasesBreast cancer survivors' perceptionsBreast cancer-specific questionnaireCancer survivors increasesCancer-specific questionnaireCancer survivors' perceptionsSelf-perceived impactSurvivorship surveySurvivorship careMedical oncologistsCare physiciansPerson visitsSurvivors increasesClinic modelCare optionsVisitsCare
2010
Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes
Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. Menopause The Journal Of The North American Menopause Society 2010, 17: 908-916. PMID: 20581724, DOI: 10.1097/gme.0b013e3181dbee1b.Peer-Reviewed Original ResearchMeSH KeywordsAdultBreast NeoplasmsChemotherapy, AdjuvantCyclohexanolsDouble-Blind MethodDrug Therapy, CombinationFemaleHot FlashesHumansHypnotics and SedativesMiddle AgedPlacebosPyridinesQuality of LifeSelective Serotonin Reuptake InhibitorsSleep Disorders, IntrinsicVenlafaxine HydrochlorideZolpidemConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsQuality of lifeSSRIs/serotonin-norepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsBreast cancer survivorsHot flashesReuptake inhibitorsCancer survivorsHypnotic agentsSSRI/SNRI therapySSRI/SNRI usersNighttime hot flashesAdjuvant endocrine therapyAssociated sleep disturbancesBreast cancer patientsProportion of respondersSubjective sleep qualitySNRI therapySNRI usersBlinded treatmentEndocrine therapyPlacebo augmentationVenlafaxine XRNocturnal awakenings
2009
Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors
Ligibel JA, Giobbie-Hurder A, Olenczuk D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes & Control 2009, 20: 1523-1528. PMID: 19434504, DOI: 10.1007/s10552-009-9358-3.Peer-Reviewed Original ResearchConceptsHigh molecular weight adiponectinBreast cancer survivorsLevels of adiponectinMolecular weight adiponectinCancer survivorsExercise interventionWeight adiponectinOverweight breast cancer survivorsUsual care control groupEndurance exercise interventionCare control groupBreast cancer riskImpact of exerciseBody fat percentageAdipocytokine levelsExercise groupSignificant changesHip circumferenceMethodsOne hundredSignificant inverse relationshipBreast cancerAdiponectinCancer riskHip measurementsAnthropometric measurements
2008
Applying a conceptual model for examining health‐related quality of life in long‐term breast cancer survivors: CALGB study 79804
Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA. Applying a conceptual model for examining health‐related quality of life in long‐term breast cancer survivors: CALGB study 79804. Psycho-Oncology 2008, 17: 1108-1120. PMID: 18314912, PMCID: PMC3930158, DOI: 10.1002/pon.1329.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantClimactericCombined Modality TherapyComorbidityDisease-Free SurvivalFemaleFollow-Up StudiesHealth BehaviorHumansLife StyleMiddle AgedNeoplasm StagingQuality of LifeRandomized Controlled Trials as TopicSick RoleSocial SupportSocioeconomic FactorsSpiritualitySurvivorsConceptsLong-term breast cancer survivorsHealth-related qualityBreast cancer survivorsHealth-oriented behaviorGlobal HRQLCancer survivorsGlobal health-related qualityBreast cancer patientsLow social supportCALGB 8541Vaginal drynessRegression modelsHot flashesMenopausal symptomsSurvivors' healthCancer patientsHeart diseaseHRQLLifestyle changesPsychosocial concernsPrevalence of problemsSurvivorsCancer diagnosisPrevalent problemSocial supportImpact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors
Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors. Journal Of Clinical Oncology 2008, 26: 907-912. PMID: 18281663, DOI: 10.1200/jco.2007.12.7357.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsExercise groupCancer survivorsInsulin levelsExercise interventionInsulin concentrationsGlucose levelsBody compositionControl groupOverweight breast cancer survivorsUsual care control groupEndurance exercise interventionCare control groupMicroU/mLSignificant decreaseBreast cancer recurrenceBreast cancer riskBreast cancer prognosisInsulin resistanceHip circumferenceCancer recurrenceBody fatHip measurementsPhysical activityCancer risk